South America mulls centralized price negotiations for hep C drugs
This article was originally published in Scrip
Members of UNASUR, the Union of South American Nations, could combine their bargaining power to drive down the price of the new hepatitis C drugs, such as Gilead's Sovaldi. If successful, such a move could set an uncomfortable precedent for drug companies selling expensive new drugs in the region.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.